Long-acting β2 agonists (LABA) are highly selective for relaxation of smooth muscle of bronchial wall. Inhaled form of LABA can produce local effect of bronchial tree, and less systemic effect. At present, two products of inhaled LABA are Salmeterol, and Formoterol. They had 12 hours duration of bronchial wall dilatation after inhaled. In clinical effects of these two drugs are similar, except Formoterol is rapid onset. For management of patients with asthma, LABA can decrease symptoms and signs, active glucocorticosteroid receptors, and decrease doses of inhaled corticosteroid. It could not administrate lonely due to little anti-inflammation effect. Combination of LABA and ICS in one device can improve lung function in moderate to severe persistent patients. Combination is superior or equal to concurrent therapy via two devices. LABA did not mask inflammation of airway and produce tolerance of short-acting β2 agonists in long-term using. For management of patients with chronic obstructive pulmonary disease (COPD), LABA role is not really clear at present. According GOLD criteria, they can prescribe for moderate to severe patients. LABA can decrease symptoms and signs, and improve lung function and quality of life in long-term using. LABA may induce cardiac arrhythmia in patients pre-existing arrhythmia and transient hypoxemia in patients with PaO2 >59 mmHg. In spite of these adverse effects, they are superior or equal to anticholinergics in management of COPD. LABA are first choice for management of patients with poor control COPD. In conclusions, LABA can free symptoms and sings and improve lung function in moderate to severe persistent asthma. Combination is superior or equal to concurrent therapy in patents with asthma. LABA or anticholinergics can consider first choice therapy drugs in patients with moderate to severe COPD.
|Number of pages||7|
|Journal||Journal of Internal Medicine of Taiwan|
|Publication status||Published - 2002 Dec 1|
All Science Journal Classification (ASJC) codes
- Internal Medicine